Sugi Predict

Sugi Predict / Compounds / SCHEMBL6773322

SCHEMBL6773322

SCHEMBL6773322

Cc1nnc(-c2ccc3ncnc(Nc4ccccc4S(=O)(=O)c4ccccc4)c3c2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 5/20 0.43
▸ CYP1A2 P05177 5/20 0.43
▸ CYP3A4 P08684 5/20 0.43
▸ LMNA P02545 4/20 0.43
▸ CLK4 Q9HAZ1 4/20 0.43
▸ TSHR P16473 4/20 0.43
▸ CYP2D6 P10635 4/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ BRAF P15056 10/20 0.43
▸ CD38 P28907 2/20 0.43
▸ RAF1 P04049 8/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPK1 P28482 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6768789 0.99 USP2 (0.43) USP2CYP1A2CYP3A4LMNACLK4
SCHEMBL6773317 0.87 BRAF (0.53) USP2CYP1A2CYP3A4LMNACLK4
SCHEMBL7005581 0.86 EGFR (0.37) BRAFCD38RAF1MAPK1KDM4E
Hydrochloric Acid SCHEMBL6768785 0.86 BRAF (0.52) USP2CYP1A2CYP3A4LMNACLK4
SCHEMBL2987644 0.78 EGFR (0.61) USP2CYP1A2CYP3A4LMNACLK4
SCHEMBL6764388 0.75 KDR (0.58) USP2CYP1A2CYP3A4LMNACLK4
Hydrochloric Acid SCHEMBL6766661 0.74 KDR (0.57) USP2CYP1A2CYP3A4LMNACLK4
SCHEMBL3324105 0.72 EGFR (0.49) CYP1A2CYP2D6CYP2C19BRAFCD38
SCHEMBL7005568 0.72 EGFR (0.45) USP2CYP1A2CYP3A4LMNACLK4
SCHEMBL6767208 0.72 EGFR (0.66) CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 — — US claimed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 — — EP claimed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 — — WO claimed
US-6828320-B2 Enzyme inhibitors; anticancer agents SMITHKLINE BEECHAM CORPORATION 2004-12-07 — — US disclosed
US-20020147214-A1 Heterocyclic compounds NOVARTIS AG (CH) 2002-10-10 — — US disclosed
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 — — US disclosed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 — — EP disclosed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147214-A1 Heterocyclic compounds BRAF, ABL1, CSK USP2 2948/4885CYP1A2 779/4885CYP3A4 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.